Companies · Biotechnology

Nuviant Medical Inc.

DALLAS · Biotechnology

Diligence memoA one-page analyst read on Nuviant Medical Inc. — recommendation, valuation, rhythm, risks.
$968K
Total raised · real
2
Rounds
0.2×
Latest step-up
Top 84%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Mon Jan 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Nuviant Medical Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.50× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Dormant
  • Last raise 11.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Nuviant Medical Inc. is one of 4293 Biotechnology companies tracked from DALLAS. By capital raised it ranks in the long tail (ahead of 17% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · Raised $825K (real) Modeled valuation $1.1M (est)$825K$1.1MPre-SeedPre-Seed · 2015-01-26 Raised $143K (real) Modeled valuation $7.9M (est)$143K$7.9MPre-Seed2015+$143KCumulative $968K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$825K
Pre-Seed extension$143K · 2015

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$7.9M
Base estimate est.
$76K
Conservative case
$89.5M
Upside case
$794K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $1.1M · Pre-Seed · modeled $7.9M · 2015-01-262015
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
11.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
541 mo
Avg between rounds
$21K/yr
Capital velocity
56.5 yr
On record since
1970
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$968K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.3× of median
This company$143K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.9M
Sector median$64.2M

Raised more than 17% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #117 of 131.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Imanis Life Sciences, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Truminim, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Direct Spinal Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Universal Biosensors Inc · Pre-Seed Raised $985K · modeled $54.4M (est)One World Lab, Inc. · Pre-Seed Raised $981K · modeled $54.2M (est)Micropharma Ltd · Pre-Seed Raised $851K · modeled $47.0M (est)Symbiotic Health, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)CVUS Ventures, LP · Pre-Seed Raised $850K · modeled $46.9M (est)ConverGene LLC · Pre-Seed Raised $850K · modeled $46.9M (est)EternoGen Aesthetics, LLC · Pre-Seed Raised $939K · modeled $46.3M (est)Genomics USA, Inc. · Pre-Seed Raised $837K · modeled $46.2M (est)Immunetics, Inc. · Pre-Seed Raised $1.5M · modeled $46.1M (est)Nuviant Medical Inc. (this company) Raised $968K · modeled $7.9M (est)Nuviant Medical Inc.
CompanyStageRaised · realValue · estvs peer med.
Imanis Life Sciences, LLCPre-Seed$1.0M$55.2M3.48×
Truminim, LLCPre-Seed$1.0M$55.2M3.48×
Direct Spinal Therapeutics, Inc.Pre-Seed$1.0M$55.2M3.48×
Universal Biosensors IncPre-Seed$985K$54.4M3.43×
One World Lab, Inc.Pre-Seed$981K$54.2M3.42×
Micropharma LtdPre-Seed$851K$47.0M2.96×
Symbiotic Health, Inc.Pre-Seed$850K$46.9M2.96×
CVUS Ventures, LPPre-Seed$850K$46.9M2.96×
ConverGene LLCPre-Seed$850K$46.9M2.96×
EternoGen Aesthetics, LLCPre-Seed$939K$46.3M2.92×
Genomics USA, Inc.Pre-Seed$837K$46.2M2.92×
Immunetics, Inc.Pre-Seed$1.5M$46.1M2.91×
Nuviant Medical Inc. this companyPre-Seed$968K$7.9M0.50×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$143K2015-01-26$794K$7.9M90%
Pre-Seed$825K$4.6M$1.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$143K2015-01-26
    • First recorded raise — entered as Pre-Seed.
Intelligence
2060 ~Q1
Modeled next raise · ~541mo cadence
$143K
Modeled next size est.range $143K$229K
0.2×
Last step-up
$21K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Alexander Ruckdaeschel5 other2015-01
DAVID B. KAYSEN3 other
CHRISTOPHER R MILLER1 other
RONALD CONQUEST1 other2015-01
William Rosellini1 other2015-01
BRIAN B BLISCHAK
HARTNUT SPITAELS2015-01
Registry & provenance

Nuviant Medical Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1638919
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Mintech-Bio, Inc.BiotechnologyPre-Seed$945K$7.2Msame sector · same stage
Artielle ImmunoTherapeutics IncBiotechnologyPre-Seed$996K$5.5Msame sector · same stage
Addiction Cure Therapeutic Sciences IncBiotechnologyPre-Seed$1.0M$5.4Msame sector · same stage
Ancilia Biosciences, Inc.BiotechnologyPre-Seed$1.0M$9.8Msame sector · same stage
Arc Techtonics, Inc.BiotechnologyPre-Seed$1.0M$9.4Msame sector · same stage
CancerVAX, Inc.BiotechnologyPre-Seed$1.0M$7.2Msame sector · same stage
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$1.0M$6.0Msame sector · same stage
EnGraft Technologies, Inc.BiotechnologyPre-Seed$1.0M$9.2Msame sector · same stage
Frequently asked
How much funding has Nuviant Medical Inc. raised?
Nuviant Medical Inc. has raised approximately $968K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Nuviant Medical Inc.'s estimated valuation?
Provath's modeled valuation for Nuviant Medical Inc. is approximately $7.9M (modeled range $76K–$89.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nuviant Medical Inc. at?
Nuviant Medical Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Mon Jan 26.
What does Nuviant Medical Inc. do and where is it based?
Nuviant Medical Inc. operates in the Biotechnology sector, based in DALLAS.
Explore related

See where Nuviant Medical Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nuviant Medical Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.